First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burns
AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cells using Aegle's proprietary and patented methods.
The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns.
AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cells using Aegle's proprietary and patented methods. The product is a composite of cell-derived nanoparticles that contain active biomolecules including proteins and nucleic acids with tissue regeneration, immunomodulation, and anti-inflammation properties.
The phase I/2a trial is a prospective, non-randomized, single arm multi-center study designed to evaluate the safety and efficacy of applying multiple administrations of AGLE-102 to deep second-degree burns. The program is being advanced for the discovery and development of allogeneic stem cell derived extracellular vesicle therapy that could offer patients accelerated healing, regenerative healing (with minimal/no scarring) and prevention of wound conversion.
"We are pleased to initiate this first-in-human trial of AGLE-102," says Shelley Hartman, Aegle's Chief Executive Officer, in a news release. "This milestone highlights our commitment to advancing extracellular therapy as an important multi-faceted approach to treating severe dermatological and immune based conditions."
Aegle anticipates the launch of a phase 1/2a study in Q4 2023 for the treatment of epidermolysis bullosa.